Xatral · DIN 02245565 · 10 mg · Prolong-Rel tablet
Limited Use, Reason for Use code 351, 352 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 351, 352 required
Write on scriptone applicable Reason for Use code, 351 or 352 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 351, 352
Reason for Use code 351
For the management of benign prostatic hyperplasia where six weeks of treatment with other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have been ineffective.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 352
For the management of benign prostatic hyperplasia where other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have produced intolerable side effects.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Xatral · DIN 02245565
Manufacturer: Sanofi Aventis Pharma; listing date 2003-01-30
Health Canada: Marketed since 2006-03-30 · brand XATRAL · ATC G04CA01 ALFUZOSIN · form Tablet (extended-release) · route Oral · ingredients ALFUZOSIN HYDROCHLORIDE 10 MG · company Sanofi-aventis canada inc · schedule Prescription
Ministry pays: $0.2601 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245565)
Source record
DIN 02245565: Xatral
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000421; group id 893; item number 2145; lccId 00121; manufacturer id SAV
Source form: Prolong-Rel Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.1352; ministry $0.2601
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245565
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69657
Interchangeable products
Alfuzosin · DIN 02447576 · $0.2601
Alfuzosin · DIN 02519844 · $0.2601
Apo-Alfuzosin · DIN 02315866 · $0.2601
Auro-Alfuzosin · DIN 02443201 · $0.2601
Sandoz Alfuzosin · DIN 02304678 · $0.2601
Shortage status: resolved shortage (ended July 20, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245565
Shortage record checked October 6, 2026